Tandem will integrate its insulin delivery systems with a new dual glucose-ketone sensor being developed by Abbott.

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in emerging markets.

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

MSF’s recent survey, conducted in partnership with T1International, revealed that an overwhelming 82% of individuals with diabetes favour insulin pens over ... Eli Lilly, and Sanofi—who ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are transforming India's health landscape. But without strong oversight, risks may out ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

This move is a milestone, he noted, as for the first time insulin is being produced as pens inside Egypt ... Approximately 15 percent of Egyptians suffer from diabetes, which makes the provision of ...

She stated that the corporate control by Eli Lilly, Novo Nordisk ... Novo Nordisk decided to cease insulin pen production to prioritize its GLP-1 medications for diabetes and obesity, like ...

80% of people with diabetes live in low- and middle-income countries, where access to insulin pens is extremely limited due primarily to high prices Eli Lilly, Novo Nordisk, and Sanofi control and ...